ARTICLE | Emerging Company Profile
TRuCs vs. CARs
Why TCR2's TRuCs could beat out CAR T therapies in solid tumors
June 23, 2017 9:34 PM UTC
TCR2 Therapeutics Inc. is creating autologous T cell therapies that it thinks will have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies. The key to the approach is fusing tumor antigen recognition domains to T cell receptors, which retains the receptors’ six intracellular subunits, as well as their natural shut-off mechanism.
The resulting therapeutics are referred to as T cell receptor fusion constructs (TRuCs). Lead candidate TC-210 is slated to enter the clinic in 2018 to treat solid tumors...
BCIQ Company Profiles
BCIQ Target Profiles